Clinical trial
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and…
NCT00308516 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00308516 |
|---|---|
| Title | 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer |
| Official title | A Phase II Study of 5-Fluorouracil, Bevacizumab (Avastin), and Radiation in the Preoperative or Adjuvant Treatment of Patients With Stage II / III Rectal Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rectal Cancer, Cancer of the Rectum, Colorectal Cancer |
| Intervention type | Drug, Procedure |
| Interventions | 5-Fluorouracil, Bevacizumab, Radiation Therapy, Oxaliplatin, Leucovorin |
| Enrollment | 66 |
| Start date | Mar 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Feb 1, 2012 |
| First posted | Mar 29, 2006 |
| Last update posted | Dec 10, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: